Group 1 - Morgan Stanley has raised the target price for MicroPort Scientific Corporation-B (02252) from HKD 30.9 to HKD 42, maintaining an "Overweight" rating and identifying it as a top choice among Chinese medical technology stocks [1] - The company has seen strong global order momentum, with cumulative surgical robot orders exceeding 170 units as of last Wednesday, up from 150 units at the end of August [1] - The installation of the Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with applications in nearly 40 countries and major hospital systems, driving strong adoption [1] Group 2 - Based on approximately 100 cumulative orders for Toumai, the company has increased its installation forecast for this year from 84 units to 105 units, primarily due to growth overseas and the assumption that orders can be converted to sales within less than a quarter [1] - The higher installation base and improved product mix are expected to lead to a gross margin improvement of 1 to 1.5 percentage points [1]